Infliximab-Induced Systemic Lupus Erythematosus

Letters1 October 2002Infliximab-Induced Systemic Lupus ErythematosusYousaf Ali, MD and Samir Shah, MDYousaf Ali, MDBrown University; Providence, RI 02906 (Ali, Shah) and Samir Shah, MDBrown University; Providence, RI 02906 (Ali, Shah)Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-137-7-200210010-00030 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Infliximab is a chimeric mouse–human monoclonal antibody recently approved by the U.S. Food and Drug Administration for the treatment of both refractory Crohn disease and rheumatoid arthritis. By directly targeting tumor necrosis factor, this new agent has allowed reduction in steroid doses and has led to improvement in the clinical signs and symptoms of inflammation. We report the development of systemic lupus erythematosus after two infusions of infliximab in a patient with Crohn disease.A 51-year-old woman with a 4-year history of Crohn colitis experienced a flare-up despite maintenance therapy with mesalamine and mercaptopurine. Mercaptopurine therapy was ...References1. Jacob CO, McDevitt HO. Tumour necrosis factor-α in murine autoimmune 'lupus' nephritis. Nature. 1988;331:356-8. [PMID: 2893286] CrossrefMedlineGoogle Scholar2. Kavanaugh A, Keenan G, DeWoody , Marsters P, Hendricks D, Clark J, et al . Long term follow up of patients treated with Remicade in clinical trials [Abstract]. Arthritis Rheum. 2001;44 Suppl 9 S81. Google Scholar3. Charles PJ, Smeenk RJ, De Jong J, Feldmann M, Maini RN. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor α: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum. 2000;43:2383-90. [PMID: 11083258] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Brown University; Providence, RI 02906 (Ali, Shah) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByPleurotoxic Drugs—an Update: Someone Else to Blame?Juvenile-onset systemic lupus erythematosus (jSLE) – Pathophysiological concepts and treatment optionsInfliximabTREG-cell therapies for autoimmune rheumatic diseasesTreatment of systemic lupus erythematosus: new advances in targeted therapyMONOCLONAL ANTIBODIESGLUCOCORTICOIDS AND DISEASE – MODIFYING ANTIRHEUMATIC DRUGSOrally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitisDrug-induced lupus: an update on its dermatologic aspectsAutoimmune diseases induced by TNF-targeted therapiesDrug-Induced Lupus due to Anti-Tumor Necrosis Factor α AgentsUso de fármacos biológicos en dermatosis fuera de la indicación aprobada. Primera parte: infliximab y adalimumabAutoimmune Diseases Induced by TNF-Targeted TherapiesLesiones cutáneas asociadas al tratamiento anti-factor de necrosis tumoral alfaToxidermie avec manifestations systémiques et sérologie lupique induites par l'infliximabAutoimmunphänomene unter Therapie mit BiologicsManagement of Psoriatic ArthritisOff-Label Use of Biologic Agents in the Treatment of Dermatosis, Part 1: Infliximab and AdalimumabInfliximab Use in Luminal Crohn's DiseaseNewer Therapeutic Approaches for Systemic Lupus Erythematosus: Immunosuppressive AgentsInfliximabEtanercept-Induced Systemic Lupus Erythematosus in a Patient with Rheumatoid ArthritisThe Benefit/Risk Profile of TNF-Blocking Agents: Findings of a Consensus PanelA lupus-like butterfly rash following infliximab therapyNewer Therapeutic Approaches for Systemic Lupus ErythematosusAggravation d'un lupus érythémateux subaigu sous infliximabDrug-Induced Lupus After Treatment With Infliximab in Rheumatoid ArthritisAnti-TNF Biological Agents in Rheumatoid Arthritis and Other Inflammatory DiseasesInfliximab-induced systemic lupus erythematosusConsiderations with the use of biological therapy in the treatment of rheumatoid arthritisThrombogenicity of TNFα in rheumatoid arthritis defined through biological probes: TNFα blockersSafety overview of new disease-modifying antirheumatic drugsThe management of dermatomyositis: current treatment optionsDrug-induced lupus erythematosusDiscoid lupus erythematosus-like eruption induced by infliximabA Review of the Use of Infliximab to Manage Cutaneous DermatosesEffets secondaires des anti-TNFαDrugs acting on the immune systemLupus Nephritis Improvement After Anti‐tumor Necrosis Factor Alpha Monoclonal Antibody (Infliximab) Treatment for Crohn's Disease: A Case ReportSafety Aspects of Infliximab in Inflammatory Bowel Disease PatientsSystemische Therapie des kutanen Lupus erythematodes. Systemic treatment of cutaneous lupus erythematosusCurrent treatment of psoriatic arthritisTwo More Drugs Associated with SIADH;Infliximab-Induced Systemic Lupus Erythematosus;Massive Tendon Xanthomas Associated with HAART;Ischemic Colitis with Sumatriptan;Fatal Hepatic Necrosis Due to Lamotrigine;Antidepressant-Induced Sexual DysfunctionInfliximabB Psoriatic ArthritisBiologic Therapies for Inflammatory Disease 1 October 2002Volume 137, Issue 7Page: 625-626KeywordsAntibodiesArthritisCrohn's diseaseDNADrug therapyLupus erythematosusRheumatoid arthritisShouldersSigns and symptomsTumor necrosis factor ePublished: 1 October 2002 Issue Published: 1 October 2002 CopyrightCopyright © 2002 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...